August 8, 2020

Journal of Hepatology Publication

Today, the Consortium of Independent Immunology Clinics (CIIC) announced a recent publication in the Journal of Hepatology, co-authored by its member, Dr. Oral Alpan.

Link to Dr. Alpan’s Journal of Hepatology article

Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients

• The group’s hypothesis was supported by analysis of data from 8 COVID-19 liver patients from the MedStar Georgetown Transplant Institute (MGTI), with 8 matched COVID-19 non-liver patient controls from SUNY Downstate Medical Center (SUNY).
  • Heightened inflammasome activity may drive acute chronic inflammation, leading to immune dysregulation and ultimately severe disease for these comorbid patients when facing COVID-19
  • Comorbidities including obesity, diabetes, hypertension, and cardiovascular disease are key predictors of COVID-19 severity
  • Amerimmune, a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, performed the immunological laboratory studies on patient samples obtained during hospitalization.

Dr. Oral Alpan is an Allergist and Clinical Immunologist and the Director of Immunopathogenesis section at O & O Alpan, LLC.  Dr. Alpan is the founder of Amerimmune, the only commercial Clinical Consultative Flow Cytometry program that provides clinical laboratory immunology services. Dr. Alpan is also the co-director of Eosinophilic Gastrointestinal Disorders unit. He has been a principal investigator in Phase II, III, IIIb and IV studies, and authored many publications in basic and clinical immunology and allergy. He has been a member of the CIIC since its inception.

The CIIC is a professional medical organization formed in 2013 and comprised of select Board Certified Immunologists in private practice throughout the USA. We provide high quality care for patients with Primary Immune Deficiency Disorders (PIDD), promote access to treatment, serve as advocates to patients and physicians who care for PIDD patients and participate in research that benefits patient care.

CIIC Mission – Provide cutting edge therapy to patients with Primary Immune Deficiency

Download PDF of Press Release